Linneo Health’s Good Manufacturing Practice (GMP) certification has been renewed, which will allow the company Linneo to continue with the research, cultivation and supply of medicinal cannabis.

Spain-based Linneo Health has had its GMP certification renewed by the Spanish Agency of Medicines and Medical Products (Agencia Española de Medicamentos y Productos Sanitarios or AEMPS), including its newly built quality control laboratory, which now has the in-house capabilities to analyse its dried flower and cannabis extracts. 

CEO, Don Bellamy, commented: “The certification of our new quality control laboratory is a major milestone in our journey to establish Linneo as a leader in the medical cannabis space, providing us with an unrivalled ability to ensure all processes are strictly adhering to global regulatory requirements. 

“We believe patients around the world deserve to be treated with cannabis medicine of the highest standard and that is why our product will always be of the highest quality for our partners. The GMP re-certification of our post-harvest facility is further evidence of Linneo’s key differentiator – our commitment to quality.”

Linneo uses its state-of-the-art technology to undertake both microbial and physical-chemical analyses of all cannabis samples, using analytical methods validated to meet European and wider global regulations.

Linneo’s post-harvest facility has also received GMP re-certification until 2024.

Quality and RA director, Maria José Garcia, added: “For our new state-of-the-art quality control laboratory to be validated by a globally recognised regulatory body means we can continue to develop and provide the highest-quality cannabis products. 

“Our advanced internal capabilities, which are uncommon for cannabis dry flower manufacturers, further reaffirm our market-leading position.”

[activecampaign form=31]